Cardiovascular Health and your Infrared Sauna
| Let’s take a look at congestive heart failure, which is a dead-end disease that kills more people in each year than cancer. The average person only lives five years once the diagnosis of congestive heart failure is made. In addition, the person is usually on at least $600 a month of prescription drugs, not to mention frequent doctor visits, x-rays, blood tests and hospitalization.
So in contrast to that bleak picture, let us examine studies done by the Mayo Clinic where pulmonary wedge pressure, shortness of breath, capacity to discontinue medications and many other limitations of congestive heart failure are enhanced with use of Far Infrared sauna therapies. In other words, FIR achieves what no medication and no surgery can, for a disease that no one should have, to which the medical profession has no answers. In addition, there is documentation that states that excessive salt carried by sweat is generally believed to be beneficial for cases of mild hypertension. This body cooling process, which takes place while using a Ohio Infrared Sauna, provides similar cardiovascular benefits to those experienced when working-out. In fact, using saunas has been described as a form of ‘passive exercise’.
This ‘passive exercise’ effect was researched by NASA and Far-Infrared was determined to be an ideal way to maintain astronauts’ cardiovascular fitness during long space flights. The sauna is also beneficial for those who do not or cannot exercise, yet want to maintain a healthy level of fitness. In addition, thinner blood vessel walls are associated with a reduced chance of heart attacks and strokes. In fact, when a patient has elevated scores of intra-medial thickness (IMT) of the carotid arteries, many doctors recommend regular use of a Far Infrared sauna to lower their risk of having a stroke.
Remember that not just any sauna will do. Ohio Far infrared saunas offer all the benefits that traditional saunas do not, and at much lower temperatures. High heat is stated to be inadvisable and poorly tolerated by heart failure patients and, in reality can be a cause of early death.
The Journal of the American Medical Association (JAMA), August 7, 1981 stated that:
“ Many of us who run do so to place a demand on our cardiovascular system, not to build big leg muscles. Regular use of a sauna may impart a similar stress on the cardiovascular system, and it’s regular use may be as effective, as a means of cardiovascular conditioning and burning of calories, as regular exercise.”
Ohio Infrared Sauna’s infrared heat therapy is one way to achieve cardiovascular conditioning effects without exerting yourself. During a sauna session, vasodilatation of peripheral blood vessels occurs which increases heart rate, cardiac output and metabolic rate. This provides a workout for your heart as the body attempts to cool itself in diverting blood from internal organs to the extremities and the skin. Heating of the body produces reflex-modulated vasodilatations in distant-body areas, even in the absence of a change in core body temperature? i.e. heat one extremity and the contra lateral extremity also dilates; heat a forearm and both lower extremities dilate; heat the front of the trunk and the hand dilates. Heating of muscles produces an increased blood flow level similar to that seen during exercise.
Research suggests that regular infrared heat therapy has been beneficial in reducing blood pressure.
Temperature elevation produces an increase in blood flow and dilation directly in the capillaries, arterioles and venues, probably through direct action on their smooth muscles. The release of bradykinin, released as a consequence of sweat-gland activity, also produces increased blood flow and vasodilatation.
Whole-body hyperthermia, with a consequent core temperature elevation, further induces vasodilatation via a hypothalamic-induced decrease in sympathetic tone on the arterial venous anatomizes. Vasodilatation is also produced by axonal reflexes and by reflexes that change vasomotor balance.
Infrared heat assists in resolution of inflammatory infiltrates, edema and exudates: The increased peripheral circulation provides the transport needed to help evacuate the edema which can help end inflammation, decrease pain and help speed healing.
Beneficial effects of Waon therapy on patients with chronic heart failure: Results of a prospective multicenter study.
Miyata M ,Kihara T,Kubozono T, Ikeda Y, Shinsato T, Izumi T, Matsuzaki M, Yamaguchi T, Kasanuki H, Daida H, Nagayama M, Nishigami K, Hirata K, Kihara K, Tei C.
Department of Cardiovascular, Respiratory and Metabolic Medicine, Graduated School of Medicine, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima 890-8520, Japan.
BACKGROUND: We conducted a prospective multicenter case-control study to confirm the clinical efficacy and safety of Waon therapy on chronic heart failure (CHF). METHODS: Patients (n=188) with CHF were treated with standard therapy for at least 1 week, and then were randomized to Waon therapy (n=112) or a control group (n=76). All patients continued conventional treatment for an additional 2 weeks. The Waon therapy group was treated daily with a far infrared-ray dry sauna at 60 degrees C for 15min and then kept on bed rest with a blanket for 30min for 2 weeks. Chest radiography, echocardiography, and plasma levels of brain natriuretic peptide (BNP) were measured before and 2 weeks after treatment. RESULTS: NYHA functional class significantly decreased after 2 weeks of treatment in both groups. Chest radiography also showed a significant decrease of the cardiothoracic ratio in both groups (Waon therapy: 57.2+/-8.0% to 55.2+/-8.0%, p<0.0001; control: 57.0+/-7.7% to 56.0+/-7.1%, p<0.05). Echocardiography demonstrated that left ventricular diastolic dimension (LVDd), left atrial dimension (LAD), and ejection fraction (EF) significantly improved in the Waon therapy group (LVDd: 60.6+/-7.6 to 59.1+/-8.4mm, p<0.0001; LAD: 45.4+/-9.3mm to 44.1+/-9.4mm, p<0.05; EF: 31.6+/-10.4% to 34.6+/-10.6%, p<0.0001), but not in the control group (LVDd: 58.4+/-10.3mm to 57.9+/-10.4mm; LAD: 46.3+/-9.7mm to 46.2+/-10.1mm; EF: 36.6+/-14.1% to 37.3+/-14.0%). The plasma concentration of BNP significantly decreased with Waon therapy, but not in the control group (Waon: 542+/-508pg/ml to 394+/-410pg/ml, p<0.001; control: 440+/-377pg/ml to 358+/-382pg/ml). CONCLUSION: Waon therapy is safe, improves clinical symptoms and cardiac function, and decreases cardiac size in CHF patients. Waon therapy is an innovative and promising therapy for patients with CHF.